High level of galectin-1 expression is a negative prognostic predictor of recurrence in laryngeal squamous cell carcinomas
| Autor: | Francois Lorfevre, Christine Decaestecker, Sabine André, Diana-Raluca Cucu, Sven Saussez, Goeffrey Mortuaire, Herbert Kaltner, Agnes Wacreniez, Gérard Toubeau, Robert Kiss, Isabelle Camby, Hans-Joachim Gabius, Dominique Chevalier |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Cancer Research Pathology medicine.medical_specialty Galectin 1 medicine.medical_treatment Recurrence otorhinolaryngologic diseases medicine Humans Lymphocytes Laryngeal Neoplasms Aged Retrospective Studies Galectin Aged 80 and over Oncogene business.industry Cancer Immunotherapy Middle Aged Cell cycle Prognosis medicine.disease Molecular medicine Gene Expression Regulation Neoplastic stomatognathic diseases Oncology Galectin-1 Carcinoma Squamous Cell Cancer research Immunohistochemistry Female business |
| Zdroj: | International Journal of Oncology. |
| ISSN: | 1791-2423 1019-6439 |
| DOI: | 10.3892/ijo.30.5.1109 |
| Popis: | Monitoring of gene-expression profiles is assumed to refine tumor characterization of laryngeal squamous cell carcinomas (LSCCs) with a therapeutic perspective. This is especially expected for adhesion/growth-regulatory effectors such as galectins, a class of endogenous lectins. Using computer-assisted microscopy, we investigated the prognostic value contributed by the quantitative determination of the immunohistochemical levels of expression of galectin-1, -3 and -7 in a series of 62 LSCCs including 42 low- and 20 high-stage LSCCs. As galectin-1 may have a key role leading to a tumor escape from immune surveillance, we also investigated whether or not the level of galectin-1 expression correlated with lymphocyte infiltration in LSCCs. The immunohistochemical determination of expression of galectin-1 is of prognostic value in human squamous laryngeal cancers. LSCCs that display high levels of galectin-1 have worse prognoses than laryngeal cancers with low levels of galectin-1 expression. Elevation of galectin-1 levels in laryngeal cancers can contribute to the process of tumor immune escape by killing the activated T-cells and other protumoral activities such as promoting motility or activity of oncogenic H-Ras proteins. The quantitative determination of galectin-1 in LSCCs is an independent prognostic marker when opposed to TNM staging. It has the potential to identify patients unlikely to benefit from T-cell-mediated immunotherapy, although the definitive effector function from its pro- and antitumoral activity profile has not been delineated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|